You are here: Industry Insights > Pharma in China

Pharma in China

Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified? Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales Xiao Yan
March 14, 2025
From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader Kevin
March 14, 2025
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
The Curtain Has Risen on the Competition for the First Generic Drug, so What Other Innovative Drugs in the Rare Disease Field Can We Look Forward to? Xiaobin
January 23, 2025
The CDE website shows Qilu Pharmaceutical applied for the marketing of nusinersen generic. Once controversial for high price, it treats SMA. Now many firms are involved, and SMA treatment progresses.
Outlook for the Development of Weight-loss Drugs in 2025 Krebs Qin
January 23, 2025
This article focuses on the challenges and opportunities for weight-loss drug development in 2025 after semaglutide and tirzepatide's market dominance. It covers GLP-1 drugs' potential in organ protection, new drug mechanisms, and pipeline products.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
Reverse Mergers Among Chinese Pharma Firms are Rising Xiaobin
January 23, 2025
Qilu Pharmaceutical applied for marketing of nusinersen injection, becoming the second in China. Nusinersen has a complex history due to high price. SMA treatment has multiple drugs and Chinese firms are making progress, with unmet needs remaining.
"Reverse Merger" Wave Rises: what's the Logic behind It? Yefenghong
January 23, 2025
Ikena Oncology and Inmagene signed a merger deal. The new firm focuses on IMG-007 for atopic dermatitis. Reverse mergers among Chinese pharma firms are rising.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.